Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. / Birkenkamp-Demtröder, Karin; Christensen, Emil; Nordentoft, Iver Kristiansen; Knudsen, Michael; Taber, Ann; Høyer, Søren; Lamy, Philippe; Agerbæk, Mads; Jensen, Jørgen Bjerggaard; Dyrskjøt, Lars.

In: European Urology, 25.09.2017.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{213df83571954a308c2d27f2afa5b739,
title = "Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis",
abstract = "Of the patients undergoing radical cystectomy, 20-80{\%} experience relapse. Minimally invasive methods for early detection of metastatic relapse after cystectomy and for monitoring ongoing therapy are urgently needed to improve individualised follow-up and treatment. Therefore, we evaluated the use of circulating tumour DNA (ctDNA) in plasma and urine to detect metastatic relapse after cystectomy and measure treatment efficacy. We exome sequenced tumour and germline DNA from patients with muscle-invasive bladder cancer and monitored ctDNA in 370 liquid biopsies throughout the disease courses by 84 personalised digital droplet polymerase chain reaction assays targeting 61 genes. Patients were prospectively recruited between 2013 and 2017. Patients with metastatic relapse had significantly higher ctDNA levels compared with disease-free patients (p<0.001). The median positive lead time between ctDNA detection in plasma and diagnosis of relapse was 101 d after cystectomy (range 0-932 d). Early detection of metastatic relapse and treatment response using liquid biopsies represents a novel, highly sensitive tool for monitoring patients, supporting clinicians, and guiding treatment decisions. PATIENT SUMMARY: Measurement of tumour-specific mutations in plasma and urine may be a powerful tool to monitor response during treatment and identify early signs of metastatic disease.",
author = "Karin Birkenkamp-Demtr{\"o}der and Emil Christensen and Nordentoft, {Iver Kristiansen} and Michael Knudsen and Ann Taber and S{\o}ren H{\o}yer and Philippe Lamy and Mads Agerb{\ae}k and Jensen, {J{\o}rgen Bjerggaard} and Lars Dyrskj{\o}t",
year = "2017",
month = "9",
day = "25",
doi = "10.1016/j.eururo.2017.09.011",
language = "English",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis

AU - Birkenkamp-Demtröder,Karin

AU - Christensen,Emil

AU - Nordentoft,Iver Kristiansen

AU - Knudsen,Michael

AU - Taber,Ann

AU - Høyer,Søren

AU - Lamy,Philippe

AU - Agerbæk,Mads

AU - Jensen,Jørgen Bjerggaard

AU - Dyrskjøt,Lars

PY - 2017/9/25

Y1 - 2017/9/25

N2 - Of the patients undergoing radical cystectomy, 20-80% experience relapse. Minimally invasive methods for early detection of metastatic relapse after cystectomy and for monitoring ongoing therapy are urgently needed to improve individualised follow-up and treatment. Therefore, we evaluated the use of circulating tumour DNA (ctDNA) in plasma and urine to detect metastatic relapse after cystectomy and measure treatment efficacy. We exome sequenced tumour and germline DNA from patients with muscle-invasive bladder cancer and monitored ctDNA in 370 liquid biopsies throughout the disease courses by 84 personalised digital droplet polymerase chain reaction assays targeting 61 genes. Patients were prospectively recruited between 2013 and 2017. Patients with metastatic relapse had significantly higher ctDNA levels compared with disease-free patients (p<0.001). The median positive lead time between ctDNA detection in plasma and diagnosis of relapse was 101 d after cystectomy (range 0-932 d). Early detection of metastatic relapse and treatment response using liquid biopsies represents a novel, highly sensitive tool for monitoring patients, supporting clinicians, and guiding treatment decisions. PATIENT SUMMARY: Measurement of tumour-specific mutations in plasma and urine may be a powerful tool to monitor response during treatment and identify early signs of metastatic disease.

AB - Of the patients undergoing radical cystectomy, 20-80% experience relapse. Minimally invasive methods for early detection of metastatic relapse after cystectomy and for monitoring ongoing therapy are urgently needed to improve individualised follow-up and treatment. Therefore, we evaluated the use of circulating tumour DNA (ctDNA) in plasma and urine to detect metastatic relapse after cystectomy and measure treatment efficacy. We exome sequenced tumour and germline DNA from patients with muscle-invasive bladder cancer and monitored ctDNA in 370 liquid biopsies throughout the disease courses by 84 personalised digital droplet polymerase chain reaction assays targeting 61 genes. Patients were prospectively recruited between 2013 and 2017. Patients with metastatic relapse had significantly higher ctDNA levels compared with disease-free patients (p<0.001). The median positive lead time between ctDNA detection in plasma and diagnosis of relapse was 101 d after cystectomy (range 0-932 d). Early detection of metastatic relapse and treatment response using liquid biopsies represents a novel, highly sensitive tool for monitoring patients, supporting clinicians, and guiding treatment decisions. PATIENT SUMMARY: Measurement of tumour-specific mutations in plasma and urine may be a powerful tool to monitor response during treatment and identify early signs of metastatic disease.

U2 - 10.1016/j.eururo.2017.09.011

DO - 10.1016/j.eururo.2017.09.011

M3 - Journal article

JO - European Urology

T2 - European Urology

JF - European Urology

SN - 0302-2838

ER -